Regenxbio Q3 2026 Results: Net Loss of $40.7M, Loss Narrows
REGENXBIO Inc. reported total assets of $466.0 million as of September 30, 2026, with a significant increase in cash and cash equivalents to $95.8 million compared to $34.5 million at year-end 2025. The company is currently managing clinical holds on its RGX-121 and RGX-111 programs while continuing development partnerships with AbbVie and Nippon Shinyaku.
- Key figure
- Net loss $40.7M